These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30651932)

  • 21. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
    Lee CH; Hötker AM; Voss MH; Feldman DR; Woo KM; Patil S; Coskey DT; Akin O; Hsieh JJ; Motzer RJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):56-62. PubMed ID: 26404107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
    Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
    Signorovitch JE; Vogelzang NJ; Pal SK; Lin PL; George DJ; Wong MK; Liu Z; Wang X; Culver K; Scott JA; Jonasch E
    Curr Med Res Opin; 2014 Nov; 30(11):2343-53. PubMed ID: 25105304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
    Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
    Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
    Pinto Á; Reig O; Iglesias C; Gallardo E; García-Del Muro X; Alonso T; Anguera G; Suárez C; Muñoz-Langa J; Villalobos-León L; Rodríguez-Sánchez Á; Lainez N; Martínez-Ortega E; Campayo M; Velastegui A; Rodriguez-Vida A; Villa-Guzmán JC; Méndez-Vidal MJ; Rubio G; García I; Capdevila L; Lambea J; Vázquez S; Fernández O; Hernando-Polo S; Cerezo S; Santander C; García-Marrero R; Zambrana F; González-Del Alba A; Lazaro-Quintela M; Castellano D; Chirivella I; Anido U; Viana A; García A; Sotelo M; Arévalo MG; García-Donas J; Hernández C; Bolós MV; Llinares J; Climent MA
    Clin Genitourin Cancer; 2022 Feb; 20(1):25-34. PubMed ID: 34789409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.
    Li JR; Yang CK; Wang SS; Chen CS; Chiu KY; Cheng CL; Yang CR; Ho HC; Ko JL; Ou YC
    Anticancer Res; 2014 Oct; 34(10):5643-7. PubMed ID: 25275068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
    Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
    Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
    J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.
    Kadono Y; Konaka H; Izumi K; Anai S; Fujimoto K; Ishibashi K; Kawai N; Kato T; Iba A; Masumori N; Yoshimura K; Mizokami A
    Contemp Clin Trials Commun; 2019 Sep; 15():100403. PubMed ID: 31312749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
    Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
    J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
    Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
    BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
    Calvo E; Grünwald V; Bellmunt J
    Eur J Cancer; 2014 May; 50(7):1321-9. PubMed ID: 24594299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.